Exocrine pancreatic secretion in response to a new CCK-analog, CCK33 and caerulein in dogs.
We studied the relative molar potencies of a newly synthetized cholecystokinin nonapeptide [Thr28,Nle31]CCK[25-33], natural porcine CCK33 and synthetic caerulein in conscious dogs with chronic gastric and pancreatic fistulas. Peptides were dissolved in albumin-containing solutions to prevent loss from solution. The three peptides were found to be equipotent on a molar basis in stimulating exocrine pancreatic secretion. As [Thr28,Nle31]CCK9 is a peptide less susceptible to oxidation than other forms of CCK, it is an interesting analog with many uses for medical and biological research.
D000818:Animals; D001639:Bicarbonates / Q000378:metabolism; D002108:Ceruletide / Q000494:pharmacology*; D002766:Cholecystokinin / Q000494:pharmacology* / Q000031:analogs & derivatives; D004285:Dogs; D005260:Female; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism
D001639:Bicarbonates; D010446:Peptide Fragments; D011506:Proteins; C042874:cholecystokinin (25-33), Thr(28)-Nle(31)-; D002108:Ceruletide; D002766:Cholecystokinin